Rucaparib: a new treatment option for ovarian cancer

References

• American Cancer Society. Key Statistics for Ovarian Cancer 2018. 2018. Accessed January 8, 2018. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
   Google Scholar
• Pennington KP, Walsh T, Harrel MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.Nature. 2011; 474(7353): 609–615.
   PubMed Web of Science ®Google Scholar
• Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8–24.
   PubMed Web of Science ®Google Scholar
• George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–296.
   PubMed Web of Science ®Google Scholar
• Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):945–956.
   PubMed Web of Science ®Google Scholar
• Moore DC, Ringley JT, Patel J. Rucaparib: a poly(ADP-ribose) polymerase inhibitor for BRCA-mutated relapsed ovarian cancer. J Pharm Pract. 2017 1;Jan:897190017743131.
   Google Scholar
• Plummer R, Jonec C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polimerase inhibitor, AG014699, in combination with temozolamide in patients with advanced solid tumors. Clin Cancer Res. 2008;14(23):7917–7923.
   PubMed Web of Science ®Google Scholar
• Kristeleit RS, Burris HA, LoRusso P, et al. Phase I/II study of oral rucaparib: final phase I results. J Clin Oncol. 2014;32(suppl 5):abstr2573.
   Google Scholar
• Swisher AM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL 2 part 1): an international, multicenter, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.
   PubMed Web of Science ®Google Scholar
• Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL 2. Gynecol Oncol. 2017;147:267–275.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after respose to platinum therapy (ARIEL3): a randomised, double blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–1961.
   PubMed Web of Science ®Google Scholar
• Clovis Oncology, Inc. A study of poly (ADP-Ribose) Polymerase inhibitor PF-01367338 in combination with several chemotherapeutic regimens ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. NLM Identifier: NCT01009190. [cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01009190
   Google Scholar
• Hoffmann-La Roche. A combination study of rucaparib and atezolizumab in participants with advanced gynecologic cancers and triple-negative breast cancer. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Apr 5]. NLM Identifier: NCT03101280. Available from: https://clinicaltrials.gov/ct2/show/NCT03101280.
   Google Scholar
• Cancer Research UK. Rucaparib (CO-338: formally called AG-014699 or PF-0136738) in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Apr 5]. NLM Identifier: NCT00664781. Available from: https://clinicaltrials.gov/ct2/show/NCT00664781
   Google Scholar
• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Di Ricerche Farmacologiche Mario Negri, foundation medicine. trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. (MITO25). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Apr 5]. NLM Identifier: NCT03462212. Available from: https://clinicaltrials.gov/ct2/show/NCT03462212.
   Google Scholar
• Clovis Oncology, Inc. ARIEL4: a study of rucaparib versus chemotherapy BRCA mutant ovarian, fallopian tube, or primary peritoneal cancer patients. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Apr 5]. NLM Identifier: NCT02855944. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02855944.
   Google Scholar
• Rubraca (rucaparib), tablets for oral use. Full Prescribing Information. Boulder (CO): Clovis Oncology, Inc; 2017.
   Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibitor: PARP1and beyond. Nat Rev Cancer. 2010;10(4):293–301.
   PubMed Web of Science ®Google Scholar
• Lin KK, Sun L, Maloney S, et al. Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. Eur J Cancer. 2015;51(suppl3):S531–S532.
   Google Scholar
• Gourley C, Friedlander M, Matulonis UA, et al. Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). JCO. 2017;35(supp15):abstr5533.
   Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–547.
   PubMed Web of Science ®Google Scholar
• Lin KK. Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer. Eur J Cancer. 2016;69(suppl1):S13.
   Google Scholar
• McCormick A, Donoghue P, Dixon M, et al. Ovarian cancers harbour defects in non-homologous end joining resulting in resistance to rucaparib. Clin Cancer Res. 2017;23(8):2050–2060.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A study to examine olaparib maintenance retreatment in patients with epithelial ovarian cancer. (OReO) ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Apr 5]. NLM Identifier: NCT03106987. Available from: https://clinicaltrials.gov/ct2/show/NCT03106987.
   Google Scholar
• Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010;16:4553–4560.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017 Jul 15;23(14):3711–3720.
   PubMed Web of Science ®Google Scholar